📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. (2018)

First Author: Quek L

Attributed to: The Oxford Single Cell Biology Consortium funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41591-018-0115-6

PubMed Identifier: 30013198

Publication URI: http://europepmc.org/abstract/MED/30013198

Type: Journal Article/Review

Volume: 24

Parent Publication: Nature medicine

Issue: 8

ISSN: 1078-8956